Download MendeleyPurine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Shi, Q., Tebben, A., Dyckman, A.J., Li, H., Liu, C., Lin, J., Spergel, S., Burke, J.R., McIntyre, K.W., Olini, G.C., Strnad, J., Surti, N., Muckelbauer, J.K., Chang, C., An, Y., Cheng, L., Ruan, Q., Leftheris, K., Carter, P.H., Tino, J., De Lucca, G.V.(2014) Bioorg Med Chem Lett 24: 2206-2211
- PubMed: 24685542
- DOI: https://doi.org/10.1016/j.bmcl.2014.02.075
- Primary Citation of Related Structures:
4NWM - PubMed Abstract:
Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivatives 3 & 8 as potent and selective BTK inhibitors. Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compound. Compound 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model. Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket. However, physical and ADME properties leading to low oral exposure hindered further development.
Organizational Affiliation:
Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, NJ 08543-4000, United States. Electronic address: qing.shi@bms.com.
